DATA GRAPHICS | Data Byte
Major pharmas had a combined $200B in cash at YE22
The top 23 biopharmas have plenty of firepower to do deals with more than $200B in cash between them
March 23, 2023 10:52 PM UTC
In a difficult biotech market, pharma M&A activity is typically expected to pick up. Some large biopharma companies have publicly stated their appetite for more business development, and the recent acquisition of Seagen by Pfizer seems to have reignited hope for more meaningful transactions this year.
How much financial power do the large biopharma companies have to support BD?...